Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.

Publication

Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.

Journal Paper/Review - Jun 1, 2023

Gaissler Andrea, Bochem Jonas, Spreuer Janine, Ottmann Shannon, Martens Alexander, Amaral Teresa, Wagner Nikolaus, Claassen Manfred, Meier Friedegund, Terheyden Patrick, Garbe Claus, Eigentler Thomas Kurt, Weide Benjamin, Pawelec Graham, Wistuba-Hamprecht Kilian

Citation

Gaissler A, Bochem J, Spreuer J, Ottmann S, Martens A, Amaral T, Wagner N, Claassen M, Meier F, Terheyden P, Garbe C, Eigentler T, Weide B, Pawelec G, Wistuba-Hamprecht K. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma. J Immunother Cancer 2023; 11

Type

Journal Paper/Review (English)

Journal

J Immunother Cancer 2023; 11

Publication Date

Jun 1, 2023

Issn Electronic

2051-1426

Brief description/objective

The need for reliable clinical biomarkers to predict which patients with melanoma will benefit from immune checkpoint blockade (ICB) remains unmet. Several different parameters have been considered in the past, including routine differential blood counts, T cell subset distribution patterns and quantification of peripheral myeloid-derived suppressor cells (MDSC), but none has yet achieved sufficient accuracy for clinical utility.